Hutchmed Partners GSK on Cancer Drug; Shares Surge 14%
SingTao · 2 SOURCESabout 3 hours ago2 MIN
Summary
Hutchmed (013) announced an exclusive global licensing agreement with GSK, granting the British pharmaceutical giant rights to develop and commercialize HMPL-A830 outside mainland China, Hong Kong, Macau, and Taiwan. The candidate drug is a first-in-class antibody-targeted toxin conjugate (ATTC) designed to treat KRAS-mutated cancers, with initial focus on colorectal, pancreatic, and lung cancers. The deal totals up to $12.95 billion in potential milestone payments plus royalties, sending Hutchmed shares surging 14% in Thursday trading.
Key Points
- Hutchmed granted GSK exclusive global rights for HMPL-A830, excluding mainland China, Hong Kong, Macau, and Taiwan
- HMPL-A830 combines a KRAS small molecule inhibitor payload with an EGFR-targeting antibody for dual targeting
- Clinical development will focus initially on colorectal, pancreatic, and lung cancers, where KRAS mutations are most prevalent
- Hutchmed receives $110 million upfront payment and up to $12.95 billion in development and commercialization milestones
- Hutchmed's Shanghai subsidiary will conduct Phase I development starting in the second half of 2026
- GSK subsidiary will handle all subsequent clinical development and commercialization outside Greater China
- Hutchmed shares rose 14% to HK$21.82, with intraday high of HK$22.30 (up 16.5%)
Why It Matters
This partnership represents Hutchmed's largest licensing deal for its proprietary payload platform, validating its ATTC technology through a global pharmaceutical leader. The dual KRAS-EGFR targeting mechanism addresses a significant unmet need for patients with KRAS-mutated cancers who lack safe, durable treatment options. For Hong Kong investors, the deal provides a concrete value inflection point as Hutchmed advances its third candidate drug from the innovative payload platform into clinical development.
This partnership represents Hutchmed's largest licensing deal for its proprietary payload platform, validating its ATTC technology through a global pharmaceutical leader. The dual KRAS-EGFR targeting mechanism addresses a significant unmet need for patients with KRAS-mutated cancers who lack safe, durable treatment options. For Hong Kong investors, the deal provides a concrete value inflection point as Hutchmed advances its third candidate drug from the innovative payload platform into clinical development.